 |
Европейская академия
|
| В начало | Энциклопедия ЕАЕН | |
Энциклопедия Европейской академии естественных наук |
||
Wang Tao
Dr. Wang Tao graduated from Fudan University (formerly Shanghai Medical University), specializing in pathogen biology (molecular oncology direction). He is the founder and chief scientist of Jiangsu Weizhen Biomedical Technology Co., Ltd., and also serves as the deputy director of the Academic Committee of the Molecular Diagnostic Innovation Technology Research Institute of the Shanghai Institute of Experimental Medicine, as well as the director of the CRISPR Technology Center, among other positions. His scientific career has been illustrious, undertaking and leading a number of key scientific and technological projects, including the National 863 Program, the Ministry of Science and Technology's international cooperation projects, Jiangsu Province's international cooperation projects, Jiangsu Province's scientific and technological achievements transformation projects, and Jiangsu Province's key research and development plans, repeatedly winning national and provincial awards.
Dr. Wang's research achievements are substantial. He has published many SCI papers as the first or corresponding author in well-known journals at home and abroad and holds 77 authorized patents, including 64 domestic invention patents and 8 international invention patents. Under his leadership, six key products have successfully obtained the National Class III Medical Device Registration Certificate, and another seven products are in the process of clinical registration.
As an outstanding scientific research expert in the field of advanced diagnostic technology, Dr. Wang Tao has been dedicated to the innovation and development of molecular diagnostic technology since founding his company in 2008. He pioneered the development of the human EGFR gene mutation detection kit (Taqman-ARMS method), marking the beginning of liquid biopsy technology in China and laying the foundation for the development of this field domestically. In addition, the S9 reagent kit he led in developing has become a landmark product with independent intellectual property rights in China due to its stable performance and high sensitivity. Globally, he was the first to create the protein marker CST4, further expanding his scientific research influence.
In recent years, Dr. Wang has shifted his research focus to CRISPR technology, aiming to solve key technical difficulties in the industrialization process, such as the development of raw materials, freeze-drying technology, and supporting reagents, successfully realizing the industrial application of CRISPR technology. His team has established a strategic partnership with the Global Innovation Diagnostic Alliance, focusing on the development of CRISPR-based immunochromatographic rapid detection technology for Mycobacterium tuberculosis nucleic acids. This technology has been sent to national-level laboratories in the United States, Vietnam, Peru, South Africa, Uganda, and other countries for validation, demonstrating China's scientific and technological strength and spirit of international cooperation in the global healthcare field.
| Энциклопедия ЕАЕН |